Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

acimtamig (AFM13)

AFM11

AFM24

AFM26

AFM28

Innate Cell Engager

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Bartlett et al.
Blood 2020; 136: 2401–2409.

link to publication

AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Reusch et al.
AACR 2020 - AFM24

A phase II open label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30 positive peripheral T cell lymphoma or transformed mycosis fungoides (REDIRECT)

Harstrick et al.
ASCO 2020 - AFM13

Redirected Optimized Cell Killing (ROCK^®): A novel multispecific antibody platform for innate immune cell engagement to fight cancer

Ellwanger et al.
NK2019 - ROCK^®

The CD30/CD16A innate cell engager AFM13 elicits polyfunctional NK cell responses effectively triggering memory-like (ML) NK cells against CD30+ targets

Marin et al.
NK2019 - AFM13

Redirected optimized cell killing (ROCK^®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

Ellwanger et al.
mAbs 2019; 11:899-918.

link to publication

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202).

Sawas et al.
15-ICML - AFM13

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

Duell et al.
J Immunother 2019; 42:180-188.

link to publication

Preclinical Characterization of the Bispecific EGFR/CD16A Innate Immune Cell Engager AFM24 for the Treatment of EGFR-Expressing Solid Tumors

Kluge et al.
AACR 2019 - AFM24

The CD30/CD16A Bispecific Innate Immune Cell Engager AFM13 Elicits Heterogeneous Single-cell NK Cell Responses and Effectively Triggers Memory Like (ML) NK Cells

Marin et al.
AACR 2019 - AFM13

1
2
3
4
5
6
7
8
9